{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:21:01Z","timestamp":1781536861435,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["23-A-19"],"award-info":[{"award-number":["23-A-19"]}]},{"name":"National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ck0106428"],"award-info":[{"award-number":["JP21ck0106428"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ck0106188"],"award-info":[{"award-number":["JP17ck0106188"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal timing of surgery following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) remains uncertain. This exploratory analysis aims to assess the impact of time to surgery (TTS) on perioperative and survival outcomes in patients with advanced ESCC enrolled in the phase III trial JCOG1109.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy were included. Within each treatment arm, patients were categorized into four TTS subgroups according to cohort quartiles. Perioperative complications, overall survival (OS), and progression-free survival (PFS) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median TTS was 35 (range, 16\u201381),\u00a038 (17\u2013109), and 41 (14\u201398)\u00a0days for the cisplatin plus fluorouracil (CF), docetaxel, cisplatin plus fluorouracil, and CF with radiotherapy (CF-RT) arms, respectively. Baseline characteristics were comparable across the TTS subgroups. Operative time and overall complication rates showed no significant differences. In the CF-RT arm, a longer TTS was associated with increased blood loss (200, 210, 300, and 370\u00a0mL) and a trend toward a higher anastomotic leakage (6%, 7%, 14%, and 18%), as well as a trend toward poorer PFS and OS, particularly at more prolonged intervals. However, across all treatment arms, OS and PFS did not differ among the TTS subgroups, with multivariable analysis revealing no consistent associations between TTS and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Time to surgery following neoadjuvant therapy did not significantly influence prognosis in advanced ESCC. Nonetheless, prolonged intervals after chemoradiotherapy may increase surgical complexity and leakage risk, in addition to elevating the potential for adverse prognostic effects associated with excessive delays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-19050-6","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:38:38Z","timestamp":1768423118000},"page":"5327-5338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109"],"prefix":"10.1245","volume":"33","author":[{"given":"Ryosuke","family":"Kita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasue","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"19050_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"19050_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.14745","volume":"14","author":"C-Q Liu","year":"2023","unstructured":"Liu C-Q, Ma Y-L, Qin Q, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2023;14:3\u201311.","journal-title":"Thorac Cancer."},{"key":"19050_CR3","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin."},{"key":"19050_CR4","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v50\u20137.","journal-title":"Ann Oncol."},{"key":"19050_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343\u201372.","journal-title":"Esophagus."},{"key":"19050_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20:373\u201389.","journal-title":"Esophagus."},{"key":"19050_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0000000000000966","volume":"260","author":"J Shapiro","year":"2014","unstructured":"Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260:807\u201313.","journal-title":"Ann Surg."},{"key":"19050_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.21037\/jgo.2017.09.11","volume":"9","author":"S Singla","year":"2018","unstructured":"Singla S, Gabriel E, Alnaji R, et al. Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer. J Gastrointest Oncol. 2018;9:73\u20139.","journal-title":"J Gastrointest Oncol."},{"key":"19050_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox062","volume":"30","author":"JS Tsang","year":"2017","unstructured":"Tsang JS, Tong DKH, Lam KO, et al. Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer. Dis Esophagus. 2017;30:1\u20138.","journal-title":"Dis Esophagus."},{"key":"19050_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.surg.2018.04.026","volume":"164","author":"J Franko","year":"2018","unstructured":"Franko J, McAvoy S. Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma. Surgery. 2018;164:455\u20139.","journal-title":"Surgery."},{"key":"19050_CR11","first-page":"874","volume":"86","author":"A-K M\u00fcller","year":"2015","unstructured":"M\u00fcller A-K, Lenschow C, Palmes D, et al. Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response. Chir Z Alle Geb Oper Medizen. 2015;86:874\u201380.","journal-title":"Chir Z Alle Geb Oper Medizen."},{"key":"19050_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/ejcts\/ezx132","volume":"52","author":"DN Ranney","year":"2017","unstructured":"Ranney DN, Mulvihill MS, Yerokun BA, et al. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2017;52:543\u201351.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg."},{"key":"19050_CR13","doi-asserted-by":"publisher","first-page":"e162743","DOI":"10.1001\/jamasurg.2016.2743","volume":"151","author":"KR Haisley","year":"2016","unstructured":"Haisley KR, Laird AE, Nabavizadeh N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. JAMA Surg. 2016;151:e162743.","journal-title":"JAMA Surg."},{"key":"19050_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/SLA.0000000000006028","volume":"278","author":"S Chidambaram","year":"2023","unstructured":"Chidambaram S, Owen R, Sgromo B, et al. Delayed surgical intervention after chemoradiotherapy in esophageal cancer: (DICE) study. Ann Surg. 2023;278:701\u20138.","journal-title":"Ann Surg."},{"issue":"91","key":"19050_CR15","first-page":"76","volume":"2018","author":"LR van der Werf","year":"1990","unstructured":"van der Werf LR, Dikken JL, van der Willik EM, et al. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer Oxf Engl. 1990;2018(91):76\u201385.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"19050_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s11605-023-05851-1","volume":"27","author":"T Maramara","year":"2023","unstructured":"Maramara T, Shridhar R, Blinn P, et al. Timing after neoadjuvant therapy predicts mortality in patients undergoing esophagectomy: a propensity score-matched analysis. J Gastrointest Surg. 2023;27:2342\u201351.","journal-title":"J Gastrointest Surg."},{"key":"19050_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2023.08.010","volume":"34","author":"K Nilsson","year":"2023","unstructured":"Nilsson K, Klevebro F, Sunde B, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015\u201324.","journal-title":"Ann Oncol."},{"key":"19050_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet Lond Engl. 2024;404:55\u201366.","journal-title":"Lancet Lond Engl."},{"key":"19050_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/jjco\/hyt061","volume":"43","author":"K Nakamura","year":"2013","unstructured":"Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752\u20135.","journal-title":"Jpn J Clin Oncol."},{"key":"19050_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer. Part I. Esophagus. 2017;14:1\u201336.","journal-title":"Esophagus."},{"key":"19050_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1245\/s10434-018-6897-4","volume":"26","author":"B Azab","year":"2019","unstructured":"Azab B, Amundson JR, Picado O, et al. Impact of chemoradiation-to-surgery interval on pathological complete response and short- and long-term overall survival in esophageal cancer patients. Ann Surg Oncol. 2019;26:861\u20138.","journal-title":"Ann Surg Oncol."},{"key":"19050_CR22","doi-asserted-by":"publisher","first-page":"doz078","DOI":"10.1093\/dote\/doz078","volume":"33","author":"F Klevebro","year":"2020","unstructured":"Klevebro F, Nilsson K, Lindblad M, et al. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study. Dis Esophagus. 2020;33:doz078.","journal-title":"Dis Esophagus."},{"key":"19050_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3892\/ol.2023.13741","volume":"25","author":"J Liu","year":"2023","unstructured":"Liu J, Zeng X, Zhou X, et al. Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer. Oncol Lett. 2023;25:155.","journal-title":"Oncol Lett."},{"key":"19050_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/SLA.0000000000003530","volume":"270","author":"JH Lef\u00e8vre","year":"2019","unstructured":"Lef\u00e8vre JH, Mineur L, Cachanado M, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer? Three years\u2019 follow-up results of the greccar-6 randomized multicenter trial. Ann Surg. 2019;270:747\u201354.","journal-title":"Ann Surg."},{"key":"19050_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/DCR.0000000000003477","volume":"68","author":"MK Collard","year":"2025","unstructured":"Collard MK, Mineur L, Nekrouf C, et al. Final results of the GRECCAR-6 trial on waiting period following neoadjuvant radiochemotherapy for locally advanced rectal cancer: 5 years of follow-up. Dis Colon Rectum. 2025;68:199\u2013208.","journal-title":"Dis Colon Rectum."},{"key":"19050_CR26","doi-asserted-by":"publisher","first-page":"e6419","DOI":"10.1097\/GOX.0000000000006419","volume":"13","author":"K Yoshizumi","year":"2025","unstructured":"Yoshizumi K, Saito N, Wu Y, et al. Adipose-derived stem cells and wound healing are progressively impaired long-term after radiotherapy in mice. Plast Reconstr Surg Glob Open. 2025;13:e6419.","journal-title":"Plast Reconstr Surg Glob Open."},{"key":"19050_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fonc.2015.00238","volume":"5","author":"MD Fountain","year":"2015","unstructured":"Fountain MD, Abernathy LM, Lonardo F, et al. Radiation-induced esophagitis is mitigated by soy isoflavones. Front Oncol. 2015;5:238.","journal-title":"Front Oncol."},{"key":"19050_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13014-018-1104-0","volume":"13","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Sheng X, Deng F, et al. Radiation-induced muscle fibrosis rat model: establishment and valuation. Radiat Oncol Lond Engl. 2018;13:160.","journal-title":"Radiat Oncol Lond Engl."},{"key":"19050_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/dote.12432","volume":"29","author":"G Lin","year":"2016","unstructured":"Lin G, Han S-Y, Xu Y-P, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus. 2016;29:1107\u201314.","journal-title":"Dis Esophagus."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19050-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:46Z","timestamp":1778869666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19050"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19050-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no conflict of interest from authors related to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}